Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
Powered By

Fabhalta (iptacopan) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating adults with paroxysmal nocturnal hemoglobinuria.

How Fabhalta Works and How It’s Taken

Fabhalta is a type of medicine called a complement factor B inhibitor. It works by blocking a protein called factor B in a part of the immune system known as the alternative complement pathway. In people with PNH, Fabhalta helps reduce the breakdown of red blood cells both inside and outside blood vessels.

Doctors prescribe Fabhalta when an adult has PNH.

Fabhalta is given as a capsule taken by mouth, typically two times a day. It can be taken with or without food.

Typical Dosing for Paroxysmal Nocturnal Hemoglobinuria

The recommended dose of Fabhalta for PNH is 200 milligrams by mouth two times a day.

This information is based on the prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.

Back to top

Fabhalta Side Effects

In clinical studies of adults taking Fabhalta for PNH, the most common side effects occurred in about 10 percent to 28 percent of people, depending on the study. They include:

  • Headache
  • Nasopharyngitis (nasal congestion, runny nose, cough, sneezing, and sore throat)
  • Diarrhea
  • Abdominal pain (stomach pain)
  • Bacterial infection
  • Viral infection
  • Nausea
  • Rash

Serious Side Effects and Warnings

Fabhalta has a black box warning for serious infections. Fabhalta can cause serious side effects that may require immediate medical attention. These include:

  • Serious infections caused by encapsulated bacteria — Fabhalta can raise the risk of severe, fast-moving infections, including infections caused by Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B.
  • Hyperlipidemia — Increased cholesterol and triglycerides, which are blood fats, can occur.

Get medical help right away if you think you are having a serious reaction.

This drug has a boxed warning, the FDA's strongest safety warning, for some of the serious risks mentioned above. A boxed warning does not mean the drug is unsafe for everyone or that everyone faces the same level of risk.

Back to top

If you experience serious side effects, you can report them to the FDA online or by calling 1-800-FDA-1088. You can also contact the drug's manufacturer.

Back to top

How to Save on Fabhalta

Novartis Pharmaceuticals Corporation, the manufacturer of Fabhalta, offers Co-Pay Plus through Novartis Patient Support. Eligible people with commercial insurance may pay as little as $0 per prescription.

To learn more, visit the Novartis Patient Support website or call 833-99FABHA (833-993-2242).

Back to top

What To Know Before Taking Fabhalta

Before starting Fabhalta, your doctor will check that your vaccines against certain encapsulated bacteria are up to date.

You should complete or update vaccines against Streptococcus pneumoniae and Neisseria meningitidis (serogroups A, C, W, Y, and B) at least two weeks before your first dose of Fabhalta, unless your doctor decides the risks of delaying treatment are greater. If Fabhalta must be started urgently and you are not up to date on these vaccines, you should get the vaccines as soon as possible and you should also receive antibiotics.

Tell your doctor if you have any allergies to iptacopan or any ingredients in Fabhalta.

Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, and supplements.

Before you take Fabhalta, tell your healthcare provider about all of your medical conditions, including if you have an infection or fever or have liver problems.

Do not take Fabhalta if you have had a serious allergic reaction to iptacopan or any of the ingredients, or if you have a serious infection caused by encapsulated bacteria (including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type B) when starting treatment.

If you miss a dose of Fabhalta, take one dose as soon as you remember (even if it is almost time for your next dose), then take your next dose at your regularly scheduled time.

If you are pregnant, planning to become pregnant, or breastfeeding while taking Fabhalta, talk with your doctor about the risks and benefits. You should not breastfeed during treatment and for 5 days after your final dose.

Fabhalta is also FDA-approved to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, and to treat adults with complement 3 glomerulopathy (C3G) to reduce protein in the urine.

Back to top

Community FAQs

These answers are fact-checked by our editorial staff.

How effective is Fabhalta?

In a 24-week study of adults with PNH who had not received complement inhibitor treatment before, 77.5 percent of people taking Fabhalta had a lasting increase in hemoglobin without needing red blood cell transfusions. This improvement was measured between days 126 and 168.

When researchers included additional lab results, the number increased to 87.5 percent. In people who had not received complement inhibitor treatment before, Fabhalta reduced lactate dehydrogenase (LDH) levels by more than 60 percent after 12 weeks. This effect continued through two years. LDH is a marker of red blood cell breakdown.

How long does Fabhalta take to work for PNH?

In clinical studies, blood tests showed changes in certain markers of complement system activity at the first measurement on day 8 in people taking Fabhalta along with anti-C5 treatment. In people who had not received complement inhibitor treatment before, changes were seen at the first measurement after four weeks of Fabhalta treatment.

Should I take Fabhalta for PNH if I have an infection?

Fabhalta should not be started if you have an unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type B.

Fabhalta can raise the risk of serious, life-threatening infections, so people taking it should be monitored for early signs of infection and evaluated right away if infection is suspected. If a serious infection happens during treatment, interruption of Fabhalta may be considered.

What tests or monitoring are needed with Fabhalta for PNH?

Before starting Fabhalta, vaccination status for encapsulated bacteria should be checked and updated. During treatment, serum lipid levels, including cholesterol and triglycerides, should be monitored periodically.

If Fabhalta is stopped in people with PNH, close monitoring for at least two weeks is recommended for signs of hemolysis, including lactate dehydrogenase changes and a sudden drop in hemoglobin.

Back to top

Thank you for subscribing!

Become a member to get even more